These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 18520056

  • 1. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
    Fukushima K, Haraya K, Terasaka S, Ito Y, Sugioka N, Takada K.
    Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
    [Abstract] [Full Text] [Related]

  • 2. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
    Fukushima K, Terasaka S, Haraya K, Kodera S, Seki Y, Wada A, Ito Y, Shibata N, Sugioka N, Takada K.
    Biol Pharm Bull; 2007 Apr; 30(4):733-8. PubMed ID: 17409512
    [Abstract] [Full Text] [Related]

  • 3. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.
    J Acquir Immune Defic Syndr; 2007 Jun 01; 45(2):201-5. PubMed ID: 17414932
    [Abstract] [Full Text] [Related]

  • 4. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A, Mallon PW, Satchell C, MacRae K, Williams KM, Schutz M, Law M, Cooper DA, Emery S.
    Clin Infect Dis; 2007 Jun 01; 44(11):1475-83. PubMed ID: 17479946
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.
    Antimicrob Agents Chemother; 2007 Apr 01; 51(4):1431-9. PubMed ID: 17296738
    [Abstract] [Full Text] [Related]

  • 6. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF.
    Clin Infect Dis; 2014 Jan 01; 58(2):268-73. PubMed ID: 24145880
    [Abstract] [Full Text] [Related]

  • 7. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.
    Antimicrob Agents Chemother; 2006 Oct 01; 50(10):3336-42. PubMed ID: 17005814
    [Abstract] [Full Text] [Related]

  • 8. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats.
    Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, Ito Y, Shibata N, Takada K.
    Biol Pharm Bull; 2005 Jan 01; 28(1):130-7. PubMed ID: 15635177
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.
    J Acquir Immune Defic Syndr; 2013 Jan 01; 62(1):60-6. PubMed ID: 23011396
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L, Hruska M, Hwang C, Shah V, Furlong M, Hanna GJ, Bertz R, Landry IS.
    Antimicrob Agents Chemother; 2015 Jul 01; 59(7):3816-22. PubMed ID: 25870057
    [Abstract] [Full Text] [Related]

  • 11. Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.
    Mugundu GM, Hariparsad N, Desai PB.
    Drug Metab Lett; 2010 Jan 01; 4(1):45-50. PubMed ID: 20201776
    [Abstract] [Full Text] [Related]

  • 12. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
    Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R.
    Antivir Ther; 2011 Jan 01; 16(2):157-64. PubMed ID: 21447864
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Hiransuthikul A, Thammajaruk N, Techatanawat I, Karachot B, Chuasuwan B, Manamuti C, Duereh M, Sawpitiporn M, Sophonphan J, Gatechompol S, Avihingsanon A, Bowonwattanuwong C, Ruxrungtham K, HIV-NAT 223 study team.
    Antivir Ther; 2018 Jan 01; 23(8):699-703. PubMed ID: 30265243
    [Abstract] [Full Text] [Related]

  • 14. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN, Baran RW, Collomb D, Beck EJ, Van de Steen O, Dietz B.
    J Med Econ; 2012 Jan 01; 15(4):796-806. PubMed ID: 22563716
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H, Zaru L, Wang R, Xu X, Pikora C, Correll TA, Eley T.
    Pediatr Infect Dis J; 2018 Jun 01; 37(6):e157-e165. PubMed ID: 29206748
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.
    AIDS; 2005 Apr 29; 19(7):685-94. PubMed ID: 15821394
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.